№ files_lp_4_process_3_084902
File format: docx
Character count: 2924
File size: 126 KB
Instructions and requirements for supervisors outlining the process, responsibilities, and contractual arrangements when submitting a supervisor statement for an applicant’s accreditation resubmission.
Year:
2026
Region / City:
United Kingdom
Subject:
Professional supervision and accreditation
Document type:
Guidance form
Organization / Institution:
British Association for Counselling and Psychotherapy (BACP)
Author:
BACP Accreditation Department
Target audience:
Supervisors and applicants for accreditation
Purpose:
To provide instructions for completing a supervisor statement as part of the accreditation resubmission process
Relevant legislation:
GDPR, Data Protection Act 2018
Sections included:
Applicant details, Supervisor details, Supervision contract, Comments, Signatures
Format:
Digital form for online submission
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
BACP Approved Progression Qualification Scheme (SCoPEd Framework Column B) – Part A & B Requirements
Year:
Not specified
Region / city:
Not specified
Subject:
Counselling and psychotherapy training
Document type:
Qualification scheme
Organization:
British Association for Counselling and Psychotherapy (BACP)
Audience:
Internal use for BACP and training providers
Qualification level:
Ofqual Level 5 or above
Minimum course duration:
One academic year
Minimum teaching hours:
120 hours
Supervised practice:
50 hours minimum
Staff requirements:
Membership in professional body, BACP or SCoPEd accreditation, responsible for course management
Delivery mode:
Mix of in-person and synchronous online teaching
Policies referenced:
Admissions, fees, equality, diversity and inclusion, placements, assessments, appeals, complaints, quality assurance, data protection
Admission requirements:
Level 4 counselling or psychotherapy qualification or equivalent, SCoPEd partner organisation membership, assessment of self-awareness, readiness, and resources for remote learning
Assessment:
Competence in theory, experiential learning, and online/remote practice
Ethical framework:
BACP Ethical Framework for the Counselling Professions
Endorsement:
BACP internal approval
Year:
2023
Region / City:
United Kingdom
Subject:
Accreditation, Professional Bodies, GDPR Compliance
Document Type:
Application Form
Organization / Institution:
BACP
Author:
BACP
Target Audience:
BACP Members, IACP Accredited Members
Period of Validity:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2021
Region / City:
UK
Theme:
Training, Placements, Online Counselling
Document Type:
Policy Update
Institution:
British Association for Counselling and Psychotherapy (BACP)
Author:
Not specified
Target Audience:
Training providers, centres, students
Period of Validity:
Ongoing, until conditions allow face-to-face training
Approval Date:
6 April 2021
Modification Date:
Not specified
Year:
Not specified
Country:
United Kingdom
Organization:
British Association for Counselling and Psychotherapy (BACP)
Document type:
Application guidance document
Scheme:
BACP Senior Accreditation Scheme
Accreditation route:
Route 2 – Level 7 qualification route
Professional field:
Counselling and Psychotherapy
Target audience:
BACP accredited members seeking senior accreditation
Eligibility requirements:
Level 7 counselling or psychotherapy qualification and minimum four years of professional practice
Required training hours:
Minimum 500 hours of tutor contact across core and post-qualifying training
Supervision requirement:
Minimum 1.5 hours of supervision per month with ongoing supervision contract
Practice requirement:
At least 50 hours of supervised practice since initial accreditation
Personal development requirement:
Minimum 160 hours of personal therapy or personal development work
Application components:
Application form, personal statement addressing five criteria, supervisor’s statement
Ethical framework:
BACP Ethical Framework and SCoPEd Framework Column C competences
Application components reviewed:
Eligibility assessment, professional community engagement, equality and inclusion, audit and evaluation, self-awareness and relational dynamics
Year:
2026
Organization:
British Association for Counselling and Psychotherapy (BACP)
Document type:
Application guidance
Target audience:
Accredited counsellors and psychotherapists seeking senior accreditation
Eligibility requirements:
Accredited BACP member, minimum four years of practice, 500+ tutor contact hours, supervised placement, 160 hours of personal therapy/personal development, ongoing supervision
Accreditation route:
Recognition of Prior Learning (RPL)
Scope:
Counselling and psychotherapy professional practice
Application components:
Personal statement covering seven criteria, supervisor’s statement, personal information
Support information:
Inclusion support for disability, learning differences, or long-term health conditions
Contact:
[email protected]
Year:
2025
Region / Country:
United Kingdom
Topic:
Counselling and psychotherapy professional accreditation
Document type:
Application guidance
Organization:
British Association for Counselling and Psychotherapy
Accreditation scheme:
BACP Individual Accreditation Scheme
Accreditation route:
Route 4 – NHS core training pathway
Target audience:
BACP registered members who completed NHS Psychotherapeutic Counselling core training
Training providers referenced:
Metanoia Institute; University of Roehampton
Partner framework:
Partnership of Counselling and Psychotherapy Bodies
Professional framework referenced:
SCoPEd framework
Related ethical standard:
BACP Ethical Framework
Eligibility requirements:
BACP registered membership, active counselling or psychotherapy practice, completion of NHS Psychotherapeutic Counselling core training, ongoing supervision
Required application components:
application form, reflective practice criteria responses, supervisor’s statement
Supervision requirement:
minimum 1.5 hours of supervision per month
Training requirement:
completion of course including 450 hours of supervised practice
Contact email:
[email protected]
Year:
2026
Organization:
British Association for Counselling and Psychotherapy (BACP)
Document type:
Application form
Target audience:
Registered BACP members seeking senior accreditation
Route:
Recognition of Prior Learning (RPL)
Requirements:
Minimum 4 years practice, completion of core training (non-BACP accredited)
Sections:
Eligibility, Portfolio of evidence, Reflective practice, Personal statement, Supervisor’s statement
Data protection:
GDPR and DPA 2018 compliance
Submission method:
Email attachment to [email protected]
Support available:
Applicants with disabilities, learning differences, or long-term health conditions
Organisation:
British Association for Counselling and Psychotherapy (BACP)
Document type:
Application form
Scheme:
Senior Accreditation Scheme
Application route:
Recognition of Prior Learning (RPL)
Professional field:
Counselling and Psychotherapy
Target applicants:
BACP Accredited Members seeking Senior Accredited Member status
Eligibility requirement:
Minimum four years of professional practice prior to application
Training requirement:
Minimum 500 hours of counselling or psychotherapy practitioner training
Supervised practice requirement:
Minimum 50 hours of supervised practice since initial accreditation
Supervision requirement:
Ongoing supervision contract of at least 1.5 hours per month
Required supporting documents:
Supervisor’s statement and training certificates
Sections included:
Eligibility, Personal Information, Practice Confirmation, Complaints and Refusal Disclosure, Training Details, Current Practice Details, Practice Hours, Supervision Arrangements
Data protection framework:
GDPR and Data Protection Act 2018
Submission method:
Email submission of completed application documents
Contact email:
[email protected]
Year:
2026
Location:
Southend, Sleaford, Kings Lynn
Course Level:
Level 4
Qualification Type:
Diploma in Therapeutic Counselling
Accreditation:
BACP Approved Practitioner Qualification
Entry Requirements:
19+ years old, Level 2 and Level 3 Counselling Certificates
Payment Options:
10 Month Plan, Payment in Full
DBS Requirement:
Enhanced DBS check required
Personal Data Protection:
GDPR compliance
Reference Requirement:
Professional reference with contact details and duration known
Attendance Requirement:
Minimum attendance mandatory
Health Information:
Disclosure of health conditions, medications, and learning requirements optional but recommended
Experiential Component:
Personal disclosure and developmental activities included
Submission Deadline:
Applications reviewed within 14 days of receipt
Email for Submission:
[email protected]
Year:
2026
Region / City:
United Kingdom
Topic:
Professional Supervision and Accreditation
Document Type:
Guidance / Application Form
Organization:
British Association for Counselling and Psychotherapy (BACP)
Author:
BACP Accreditation Department
Target Audience:
Supervisors and applicants seeking individual accreditation
Accreditation Route:
Streamlined Route
Legal Compliance:
GDPR and Data Protection Act 2018
Contact Information:
01455 883300, [email protected]
Year:
2021
Region / City:
United Kingdom
Topic:
Academic accreditation, psychotherapy
Document Type:
Handbook
Organization / Institution:
BACP
Author:
Not specified
Target Audience:
BACP registered members applying for senior accreditation
Period of Validity:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Year:
2023
Region / city:
Australia
Topic:
Oncology, Pharmaceuticals
Document Type:
Resubmission
Institution:
Australian Government, Pharmaceutical Benefits Advisory Committee
Author:
AstraZeneca Pty Ltd.
Target Audience:
Healthcare professionals, regulatory bodies
Effective Period:
Ongoing
Approval Date:
November 2021
Date of Changes:
November 2021
Note:
Year
Document Type:
Assessment Form
Institution:
Pearson
Author:
Pearson
Target Audience:
Students, Assessors
Year:
2022
Country:
Australia
Therapeutic area:
Oncology
Disease:
Endometrial cancer
Biomarker status:
Mismatch repair deficient (dMMR)
Medicine name:
Dostarlimab
Brand name:
Jemperli
Dosage form:
Solution concentrate for intravenous infusion
Sponsor:
GlaxoSmithKline Australia Pty Ltd
Regulatory body:
Pharmaceutical Benefits Advisory Committee
Submission type:
Standard Re-entry submission
Requested listing:
Section 100
Comparator treatments:
Standard of care chemotherapy; pembrolizumab plus lenvatinib; pembrolizumab monotherapy
Clinical trial referenced:
GARNET
Approval status:
Provisional approval
Indication:
Recurrent or advanced endometrial cancer after platinum-containing regimen
Decision context:
PBS listing consideration
Period covered:
Up to November 2022
Drug name:
Apremilast
Brand name:
Otezla
Dosage form:
Tablet
Strength:
30 mg
Pack composition:
4 tablets of 10 mg, 4 tablets of 20 mg, 19 tablets of 30 mg
Sponsor:
Amgen Australia Pty Ltd
Regulatory status:
TGA registered
TGA registration date:
19 March 2015
Indication:
Severe plaque psoriasis
Previous indication:
Psoriatic arthritis and moderate to severe plaque psoriasis
Application type:
Minor resubmission
Requested listing:
PBS General Schedule, Authority Required (STREAMLINED)
Comparator:
Cyclosporin
Clinical population:
Patients with severe plaque psoriasis intolerant of or contraindicated to methotrexate
Primary outcome:
PASI-75 at 16 weeks
Clinical claim:
Non-inferior comparative efficacy and safety versus cyclosporin
Regulatory body:
Pharmaceutical Benefits Advisory Committee
Submission history period:
2015–2018
Geographic scope:
Australia
Source type:
Public summary document excerpt
Year:
2019–2020
Region / country:
Australia
Subject:
Chronic migraine treatment and drug listing
Document type:
Public Summary Document (PSD)
Organization / authority:
Pharmaceutical Benefits Advisory Committee (PBAC), TGA
Drug:
Galcanezumab (Emgality)
Other drugs referenced:
Fremanezumab, Erenumab, Botox
Target population:
Adults with chronic migraine unresponsive to at least three prophylactic migraine medications
Administration form:
Injection 120 mg/1 mL pre-filled pen
Prescription restrictions:
Streamlined listing, treatment by neurologist required, specific clinical criteria for migraine frequency and prior treatment response
Consumer input:
Included 186 individuals, 2 health professionals, 1 organization
Cost analysis:
Cost-minimisation analysis (CMA) versus Botox
Risk sharing arrangement:
Included, with expenditure cap adjustments
Year:
2019
Region / city:
Australia
Theme:
Oncology, Chemotherapy
Document type:
Resubmission for PBS listing
Organ / institution:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
Bristol-Myers Squibb Australia Pty Ltd
Target audience:
Medical professionals, PBAC members
Validity period:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Medicine:
Midazolam oromucosal solution in pre-filled syringe
Brand name:
Zyamis®
Sponsor:
Clinect Pty Ltd
Dosage forms:
2.5 mg/0.25 mL; 5 mg/0.5 mL; 7.5 mg/0.75 mL; 10 mg/1 mL
Indication:
Treatment of generalised convulsive status epilepticus (GCSE) in patients over 6 months of age
Regulatory authority:
Therapeutic Goods Administration (TGA)
ARTG listing date:
22 April 2022
Advisory body:
Pharmaceutical Benefits Advisory Committee (PBAC)
Submission type:
Early re-entry resubmission
Requested listing:
Section 85 Authority Required (telephone/online)
Additional request:
Prescriber Bag Schedule listing for Medical Practitioners
Comparative medicine:
Midazolam hydrochloride injection 5 mg/mL
Proposed maximum quantity:
2 pre-filled syringes per prescription
Estimated financial impact:
$20 million to < $30 million over six years
Previous consideration:
July 2022 PBAC meeting
Source:
Public Summary Document (PSD), July 2022
Year:
2021
Region / City:
Australia
Document Type:
Public Summary Document (PSD)
Organization:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Not specified
Target Audience:
Healthcare professionals, Medical Practitioners
Period of Effect:
2021-2022
Approval Date:
15 July 2021
Revision Date:
November 2021